| 生物活性 |
Physalin B is an orally active anti-inflammatory and anticancer agent isolated from Physalis alkekengi L. var. Franchetii that inhibits the activation of NF-κB, NLRP3 inflammasome, STAT3, PI3K/Akt and Hedgehog signaling pathways, modulates the phosphorylation levels of GSK-3β, p38 MAPK, ERK1/2 and JNK, promotes NRF2 nuclear translocation, reduces the levels of pro-inflammatory cytokines and factors, induces mitochondrial reactive oxygen species (mito-ROS) production, apoptosis, G2/M cell cycle arrest and incomplete autophagy, alters cytoskeletal structure and alleviates oxidative stress, decreases cancer cell viability, ameliorates hepatic and pulmonary tissue injury and attenuates liver fibrosis, and can be used for research related to ulcerative colitis, breast cancer, acute lung injury, colon cancer, non-alcoholic steatohepatitis, liver fibrosis, lung cancer, pancreatic cancer, lymphoma, ovarian cancer, sarcoma and leukemia. |
体外研究 (In Vitro) |
Physalin B (0.25-16.0 µM; 24 h) 在作用 24 h 后,浓度高达 1.0 µM 时对 RAW 264.7 细胞无细胞毒性,但在浓度 ≥2.0 µM 时会诱导显著的浓度依赖性细胞毒性。 Physalin B (0.25-1.0 µM; 2 h pre-incubation, followed by 24 h co-incubation with 1 µg/mL LPS) 可显著抑制 LPS 诱导的 RAW 264.7 细胞中 TNF-α、IL-6 和 IL-1β 的产生。 Physalin B (0.63-40 μM; 12-72 h) 可呈浓度和时间依赖性降低 MCF-7、MDA-MB-231 和 T-47D 细胞的活力,在 40 μM 作用 24 h 后细胞近乎完全死亡。 Physalin B (2.5-10 μM; 48 h) 可将 MCF-7 细胞的凋亡率分别提升至 16.4%、21.6% 和 35.4%。 Physalin B (0.31-10 μM; 72 h) 可强效抑制 HCT116 细胞的活力,其 IC50 为 1.35 μM。 Physalin B (2.5-10 μmol/L; 12-36 h) 可通过促进固缩、凋亡小体形成以及 PARP 和 caspase-3 的切割,在 2.5、5 和 10 μmol/L 浓度下作用 12-36 h 诱导 HCT116 细胞凋亡。 Physalin B (0.25-40 μM; 48 h) 不影响人肝细胞 L02 的活力。 Physalin B (0.25-1 μM; 48 h) 可呈剂量依赖性减少游离脂肪酸诱导的 L02 肝细胞内的脂质积累。 Physalin B (0.25-1 μM; 48 h) 可呈剂量依赖性降低游离脂肪酸 (FFA) 诱导的 L02 细胞内的 ROS 水平。 Physalin B (2.5-5 μM; 30 min) 可抑制 TNFα 诱导的 293T-NF-κB 细胞中 NF-κB 的激活,在 5 μM 浓度下观察到最大 85% 的抑制率。 Physalin B (孵育 24 h) 可降低 LX-2 细胞活力,其 IC50 约为 5 μM。
Cell Viability Assay
| Cell Line: |
mouse monocyte-macrophage RAW 264.7 cells |
| Concentration: |
0.25-16.0 µM |
| Incubation Time: |
24 h |
| Result: |
Showed no cytotoxicity (cell viability unchanged relative to control) at concentrations of 0.25, 0.5, and 1.0 µM after 24 h. Reduced cell viability to 88.50% at 2.0 µM. Increased cytotoxicity significantly with higher concentrations (4.0, 8.0, 16.0 µM), leading to progressively lower cell survival rates. |
ELISA Assay
| Cell Line: |
LPS-stimulated mouse monocyte-macrophage RAW 264.7 cells |
| Concentration: |
0.25-1.0 µM |
| Incubation Time: |
2 h pre-incubation, followed by 24 h co-incubation with 1 µg/mL LPS |
| Result: |
Significantly inhibited the LPS-induced release of TNF-α, IL-6, and IL-1β at all tested concentrations, with statistically significant reductions (P < 0.01 to P < 0.001) relative to the LPS-only model group. |
Cell Viability Assay
| Cell Line: |
MCF-7, MDA-MB-231, T-47D |
| Concentration: |
0.63-40 μM |
| Incubation Time: |
12 h, 24 h, 48 h, 72 h |
| Result: |
Caused less than 20% cell death across all three cell lines at concentrations below 2.5 μM even after 72 h. Reduced cell viability in a concentration- and time-dependent manner at 2.5-40 μM. Reduced MCF-7 cell viabilities to 71.8% (12 h), 52.0% (24 h), 43.0% (48 h), 31.8% (72 h) at 20 μM. Reduced MDA-MB-231 cell viabilities to 78.7% (12 h), 36.2% (24 h), 28.0% (48 h), 33.2% (72 h) at 20 μM. Reduced T-47D cell viabilities to 85.3% (12 h), 29.9% (24 h), 16.5% (48 h), 10.3% (72 h) at 20 μM. Nearly completely killed all three cell lines at 40 μM after 24 h or longer incubation. |
Apoptosis Analysis
| Cell Line: |
MCF-7 |
| Concentration: |
2.5-10 μM |
| Incubation Time: |
48 h |
| Result: |
Increased the apoptotic rate of MCF-7 cells in a concentration-dependent manner: from baseline to 16.4% (2.5 μM), 21.6% (5 μM), and 35.4% (10 μM). |
Apoptosis Analysis
| Cell Line: |
human HCT116 colon cancer cells |
| Concentration: |
2.5-10 μmol/L (nuclear staining: 5-10 μmol/L; Western blot: 2.5-10 μmol/L) |
| Incubation Time: |
12-36 h (nuclear staining: 24 h; Western blot: 12-36 h) |
| Result: |
Induced pyknosis and apoptotic body formation at 5 and 10 μmol/L after 24 h. Dose- and time-dependently induced cleavage of PARP and caspase-3, with detectable cleavage starting at 12 h for 10 μmol/L, and increasing at 24 and 36 h across all tested concentrations. |
|
体内研究 (In Vivo) |
Physalin B (10-20 mg/kg;腹腔注射) 可通过改善临床症状、减轻结肠损伤、恢复免疫器官功能及抑制多条炎症信号通路 (NF-κB、STAT3、β-arrestin1、NLRP3 炎症小体),显著缓解 DSS 诱导的 BALB/c 小鼠急性溃疡性结肠炎。 Physalin B (15 mg/kg;灌胃;每日;连续 7 天) 可通过激活 PI3K/Akt 通路抑制 NF-κB 和 NLRP3 信号传导、减少炎性细胞因子产生并抑制肺组织细胞凋亡,从而保护小鼠免受 LPS 诱导的急性肺损伤。 Physalin B (3.25-600 mg/kg;口服;每日;2-4 周) 可通过激活自噬及 P62-KEAP1-NRF2 抗氧化通路,呈剂量依赖性改善雄性 C57BL/6J 小鼠中 MCD 诱导的非酒精性脂肪性肝炎 (NASH);其中 30 mg/kg 剂量对肝损伤、脂质蓄积、炎症及氧化应激的抑制作用最强,且剂量高达 600 mg/kg 时未观察到毒性。 Physalin B (腹腔注射;1-5 mg/kg;隔日一次;持续 4 周) 可减轻 CCl4 (MS-X51453) 诱导的雄性 C57BL/6J 小鼠肝纤维化,降低胶原沉积水平、肝损伤标志物水平及纤维化相关基因的表达。 Physalin B (1-5 mg·kg−1;腹腔注射;隔日一次;共 14 天) 可改善雄性 C57BL/6J 小鼠中胆管结扎诱导的肝损伤与纤维化,减轻病理损伤、胶原沉积及纤维化标志物的表达。
| Animal Model: |
BALB/c (male, 20 g) |
| Dosage: |
10 mg/kg; 20 mg/kg |
| Administration: |
i.p. |
| Result: |
Significantly reversed DSS-induced colon shortening, with the 20 mg/kg dose showing greater efficacy than positive control SASP. Significantly prevented body weight loss in DSS-treated mice by day 7. Significantly reduced the DAI scores of DSS-treated mice, indicating improved disease symptoms. Significantly alleviated DSS-induced colonic pathological damage (including epithelial erosion, crypt loss, and immune cell infiltration) and reduced histological scores, with the 20 mg/kg dose showing stronger efficacy than SASP. Significantly inhibited elevated colonic MPO activity in DSS-treated mice, reducing inflammatory cell infiltration. Significantly reversed DSS-induced splenomegaly (reduced spleen coefficient) and thymus atrophy (increased thymus coefficient), restoring immune organ function. Significantly reduced elevated colonic levels of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in DSS-treated mice, with the 20 mg/kg dose showing stronger efficacy than SASP. Significantly suppressed DSS-induced activation of the NF-κB pathway, as measured by reduced phosphorylation of NF-κB p65 and IκBα. Significantly suppressed DSS-induced activation of the STAT3 pathway, as measured by reduced phosphorylation of STAT3. Significantly reduced DSS-induced upregulation of β-arrestin1 protein levels in colon tissue. Significantly suppressed DSS-induced activation of the NLRP3 inflammasome, as measured by reduced protein levels of NLRP3, ASC, and IL-1β. |
| Animal Model: |
BALB/c (male, 10-12 weeks old, 20-22 g, LPS-induced septic ALI) |
| Dosage: |
15 mg/kg |
| Administration: |
i.g.; daily; 7 days |
| Result: |
Significantly reduced LPS-induced inflammatory cell infiltration in lung tissue. Decreased lung wet/dry weight ratios and myeloperoxidase activity in lung tissue, blood, and bronchoalveolar lavage fluid. Mitigated LPS-induced alterations in arterial blood gas parameters (pH, HCO3-, Hgb, PCO2, PO2, BE). Reversed LPS-induced downregulation of anti-apoptotic protein Bcl-2 and upregulation of pro-apoptotic protein Bax. Reduced LPS-increased caspase-3 and caspase-9 activity in lung tissue. Significantly attenuated LPS-induced increases in total inflammatory cells, neutrophils, macrophages, and lymphocytes in blood and bronchoalveolar lavage fluid. Decreased LPS-elevated protein levels of TNF-α, IL-1β, and IL-6 in blood, bronchoalveolar lavage fluid, and lung tissue, as well as their mRNA levels in lung tissue. Blocked LPS-induced phosphorylation of NF-κB (p65) and IκBα in lung tissue. Inhibited LPS-upregulated NLRP3, ASC, and IL-1β protein levels and caspase-1 activity, while increasing pro-IL-1β protein levels in lung tissue. Reversed LPS-induced downregulation of phosphorylated PI3K/Akt in lung tissue. Had protective effects abolished by co-administration of PI3K inhibitor LY294002, including restored NF-κB and NLRP3 activation and increased inflammatory cell influx in lung tissue. |
| Animal Model: |
C57BL/6J (male, 5 weeks old, 20-22 g, NASH induced by MCD diet for 4 weeks) |
| Dosage: |
3.25 mg/kg; 7.5 mg/kg; 15 mg/kg; 30 mg/kg; 300 mg/kg; 600 mg/kg |
| Administration: |
p.o.; daily; 4 weeks (for 3.25-30 mg/kg); p.o.; daily; 2 weeks (for 300-600 mg/kg) |
| Result: |
Reversed MCD-induced decreases in body weight and significantly reduced the liver-to-body weight ratio at 30 mg/kg dose compared to the MCD model group. Reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in a dose-dependent manner, with the 30 mg/kg dose showing the strongest reduction. Decreased hepatic total triglyceride (TG) and total cholesterol (TC) levels in a dose-dependent manner. Improved liver injury, hepatocyte ballooning, and inflammatory cell infiltration in a dose-dependent manner; significantly reduced the NAFLD Activity Score (NAS) across all doses. Significantly decreased hepatic mRNA expression of inflammatory cytokines Il-6, Il-1β, and Tnf-α in a dose-dependent manner, and reduced F4/80 mRNA levels. Reduced hepatic lipid accumulation in a dose-dependent manner, with the 30 mg/kg dose nearly eliminating large lipid droplets. Increased hepatic LC3-II protein levels and the LC3-II/LC3-I ratio in a dose-dependent manner. Increased hepatic NRF2 and P62 protein expression in a dose-dependent manner, and upregulated hepatic mRNA expression of NRF2 target genes Nqo-1 and Ho-1 in a dose-dependent manner. Showed no abnormal clinical signs or pathological changes in heart, liver, spleen, or kidney tissues at 300 mg/kg and 600 mg/kg oral doses for 2 weeks. |
| Animal Model: |
C57BL/6J (male, 5 weeks old, 18-20 g, specific-pathogen-free, liver fibrosis induced by CCl4 injection) |
| Dosage: |
1 mg·kg-1; 2.5 mg·kg-1; 5 mg·kg-1 |
| Administration: |
i.p.; every other day; 4 weeks |
| Result: |
Ameliorated CCl4-induced hepatic inflammatory cell infiltration, central venous wall thickening, and fibrous hyperplasia. Reduced Sirius Red and Masson's trichrome-stained collagen deposition, fibroplasia, and bridging fibrosis. Decreased elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Lowered hepatic hydroxyproline content. Significantly reduced mRNA expression of fibrogenic genes (α-sma, Col1a1, Tgfβ1, Timp1) as well as protein levels of α-SMA and COL1A1 in liver tissues. |
| Animal Model: |
C57BL/6J (male, 5 weeks old, 18-20 g, specific-pathogen-free, liver fibrosis induced by bile duct ligation surgery) |
| Dosage: |
1 mg·kg-1; 2.5 mg·kg-1; 5 mg·kg-1 |
| Administration: |
i.p.; every other day; 14 days |
| Result: |
Ameliorated BDL-induced liver parenchyma necrosis. Reduced newly formed bile ducts (assessed by CK19 staining). Decreased Sirius Red and Masson's trichrome-stained collagen deposition. Lowered liver-to-body weight ratio and elevated serum biochemical markers (including alkaline phosphatase (AKP), γ-glutamyl transpeptidase (γ-GT), total bile acid (TBA), total bilirubin (TBiL)). Reduced hepatic hydroxyproline content. Significantly decreased mRNA and protein levels of fibrogenic markers in liver tissues. |
|